Decreased anticoagulant response to tissue factor pathway inhibitor in @entity1 with XXXX and otherwise no evidence of hereditary or acquired @entity49 .

@entity1 @entity49 @entity11524 @entity1031 @entity715 @entity1211
No relevant deficiency of @entity11524 or genetic polymorphisms could thus far consistently be associated with @entity1211 . We hypothesized that the substrates of the @entity11524 protein, including FVII or FX (rather than the protein itself) could induce a @entity49 state. We created a novel TF-based clotting assay that evaluated the anticoagulant response to exogenously added recombinant @entity11524 . The response to @entity11524 was expressed as the ratio of the clotting time with and with-out @entity11524 . By using 118 healthy controls, we established a reference range between 1.31 and 1.93 (mean value +/-2 standard deviations (SD), 1.62 +/-0.31). We then evaluated samples from 120 @entity1 with a history of @entity1211 but no evidence of hereditary and acquired @entity49 . The range Coagulation Laboratory, Division of Haematology, University Hospital of Zurich, Zurich, Switzerland of the @entity1 ' ratios was significantly (P < 0.001) lower, falling between 1.2 and 1.78 (mean value +/-2 SD, 1.49 +/-0.29). Of the 120 @entity1 , 39 (32.5%) had a @entity11524 sensitivity ratio below the 10th percentile of the controls, compared with 11 (9.3%) of the healthy controls. The crude odds ratio for @entity49 for subjects with a @entity11524 sensitivity ratio below the 10th percentile was 13 (95% CI; range, 3.1 to 54.9) compared with those with a ratio above 1.8 (90th percentile). @entity1 with idiopathic @entity1031 did not have a decreased @entity11524 sensitivity ratio more often than @entity1 with @entity715 with a circumstantial risk factor. Based on these results, a reduced response to @entity11524 may lead to an increased risk of @entity49 .
